Immunosuppressive therapy is more effective than interferon in neuromyelitis optica-Reference-Cited by-同舟云学术

Immunosuppressive therapy is more effective than interferon in neuromyelitis optica

Published:2007-03 Issue:2 Volume:13 Page:256-259
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Papeix C¹,Vidal J-S²,Seze J De³,Pierrot-Deseilligny C¹,Tourbah A¹⁴,Stankoff B¹⁵,Lebrun C⁶,Moreau T⁷,Vermersch P³,Fontaine B¹,Lyon-Caen O¹,Gout O⁸

Affiliation:

1. Department of Neurology, Hôpital de la Salpêtrière, Paris, France

2. Institut National de la Santé et de la Recherche Médicale Unité 708, Hôpital de la Salpêtrière, Paris, France

3. Department of Neurology, CHU de Lille, Lille, France

4. Department of Internal Medicine, CHNO XV/XX, Paris, France

5. Centre d'Investigation Clinique, Hôpital de la Salpêtrière, Paris, France

6. Department of Neurology, CHU de Nice, Nice, France

7. Department of Neurology, CHU de Dijon, Dijon, France

8. Department of Neurology, Fondation Ophtalmologique A. de Rothschild, Paris, France

Abstract

To determine long-term treatment (LTT) of neuromyelitis optica (NMO), we retrospectively reviewed therapies of 26 patients with NMO followed in five French neurological departments. To assess LTT efficacy, the probability of relapse free after LTT was analysed. Patients were divided into two groups according to the first treatment receiving interferon beta (IFN Group, seven patients) or immunosuppressants (IS Group, 19 patients). The probability of relapse was significantly lower in the IS Group (P = 0.0007). From our results, interferon beta is not recommended, and one of the best current therapeutic options for NMO appears to be immunosuppressants. Multiple Sclerosis 2007; 13: 256–259. http://msj.sagepub.com

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458506070732

Reference12 articles.

1. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

2. Devic's neuromyelitis optica: A clinicopathological study of 8 patients

3. Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprine

4. An open label study of the effects of rituximab in neuromyelitis optica

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of the advances in neuromyelitis optica spectrum disorder;Autoimmunity Reviews;2023-12

2. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management;Journal of Neurology;2023-09-07

3. Long Term Misdiagnosis of Neuromyelitis Optica Spectrum Disorder Patients with Multiple Sclerosis;2023-01-10

4. Neuromyelitis Optica Spectrum Disorders (NMOSD);Current Treatment Options in Neurology;2022-03-29

5. Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera;International Journal of Molecular Sciences;2022-03-03